We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Rash of Promising DMD Treatments Continues With Marathon’s Deflazacort
Rash of Promising DMD Treatments Continues With Marathon’s Deflazacort
The FDA has granted rare pediatric disease designation to another investigational drug to treat Duchenne muscular dystrophy, this time to Marathon Pharmaceuticals’ deflazacort.